DNA Q2 2024 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$418M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M-30.2% YoY

Gross Profit

$42M75.6% margin

Operating Income

-$223M-396.7% margin

Net Income

-$217M-386.4% margin

EPS (Diluted)

$-4.23

QoQ Revenue Growth

+48.1%

Cash Flow

Operating Cash Flow

-$84M

Free Cash Flow

-$111M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$792M

Stockholders' Equity

$833M

Cash & Equivalents

$730M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$81M	-30.2%
Gross Profit	$42M	$62M	-32.0%
Operating Income	-$223M	-$184M	-21.1%
Net Income	-$217M	-$173M	-25.3%

Revenue Segments

Service

$20M100%